B. Riley Securities to Host Radiation Oncology Virtual Investor Day on February 22, 2022

The B. Riley Securities Healthcare Equity Research Team is hosting a Radiation Oncology Investor Day on February 22, 2022, to provide insights into the current state and future direction of the radiation oncology field by bringing together innovative companies and independent experts. Senior oncology-focused analyst and trained radiochemist Justin Walsh, PhD, will conduct fireside chats with key public and private companies working in the space, as well as an expert KOL panel discussion. Topics are expected to range from understanding and overcoming supply chain and logistical challenges unique to radiopharmaceuticals, to the potential competitive and/or complementary roles of external beam and targeted radiotherapies.

"While external beam radiation therapy has remained at the forefront of cancer treatment for over a century, recent innovations in precision/targeted medicine and next-generation medical devices have advanced the field to the point where patients are beginning to see significant improvements in outcomes," remarked Justin Walsh. "With sustained interest and investment from Big Pharma and the success of approved/late-stage radiopharmaceuticals, we believe that the field is poised to benefit patents across cancer indications and look forward to highlighting innovators who have made it their mission to ensure this occurs."

Expert Panel Discussion: "Expanding Opportunities In Radiation Oncology - From Reactor To Bedside"

Featuring panel participants: Ravi Patel, MD, PhD (assistant professor, University of Pittsburgh School of Medicine, and radiation oncologist at UPMC Hillman Cancer Center), Kevin Staton, MBA (Head of Project Management at Evergreen Theragnostics), & Leila Safavi (PhD, CEO and Co-Founder of Purist Inc.)

The following list of companies participating in fireside chats is current as of today's date and may be subject to change:

· Actinium Pharmaceuticals, Inc. (ATNM)

· Alpha Tau Medical

· Fusion Pharmaceuticals (FUSN)

· GT Medical Technologies

· Oncoinvent A/S

· POINT Biopharma Global Inc. (PNT)

· Viewpoint Molecular Targeting, Inc.

This invitation-only virtual event is reserved for clients of the firm. Interested participants should contact their B. Riley representative.

For more information, visit www.brileysecurities.com.

To view our upcoming events, visit www.brileyfin.com/events or view our LinkedIn page.

About B. Riley Securities

B. Riley Securities provides a full suite of investment banking, corporate finance, advisory, research, and sales and trading services. Investment banking services include initial, secondary and follow-on offerings, institutional private placements, merger and acquisition (M&A) advisory, SPACs, corporate restructuring and recapitalization. B. Riley is nationally recognized and highly ranked for its proprietary small-cap equity research. The firm is a wholly owned subsidiary of B. Riley Financial. Please see www.brileyfin.com/disclosures for disclosures about B. Riley Securities Research.

B. Riley Financial provides collaborative solutions tailored to fit the capital raising and business advisory needs of its clients and partners. B. Riley operates through several subsidiaries that offer a diverse range of complementary end-to-end capabilities spanning investment banking and institutional brokerage, private wealth and investment management, financial consulting, corporate restructuring, operations management, risk and compliance, due diligence, forensic accounting, litigation support, appraisal and valuation, auction and liquidation services. For more information, please visit www.brileyfin.com.

Contacts

Event Inquiries

Jolene Glasser

conference@brileyfin.com

(818) 746-9524

Media Inquiries

Jo Anne McCusker

press@brileyfin.com

(646) 885-5425